GSK Advances Share Buyback Program with Recent Repurchase

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

GlaxoSmithKline has announced the repurchase of 348,430 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 9, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and following this purchase, GSK holds 219,571,109 ordinary shares in treasury. The buyback program is expected to enhance shareholder value and optimize the company’s financial position.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GSK’s overall stock score reflects strong technical momentum and positive corporate events, despite concerns over valuation and leverage risks. The company’s strategic focus on specialty medicines and robust earnings outlook further support the investment case.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company engaged in the development, manufacturing, and marketing of pharmaceuticals, vaccines, and consumer healthcare products. The company focuses on improving the quality of human life by enabling people to do more, feel better, and live longer.

Average Trading Volume: 10,052,714

Technical Sentiment Signal: Strong Buy

Current Market Cap: £61.32B

Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.